IGF-1 LR3 1mg

Receptor Grade IGF-1 LR3 (Long Arginine 3 IGF-1) is a synthetic 83-amino acid variant of naturally occurring Insulin-like Growth Factor-1 (IGF-1), engineered with an additional arginine residue at position 3 and a 13-amino acid N-terminal extension. This structural modification reduces its binding affinity to IGF-1 binding proteins (IGFBPs), potentially increasing its bioavailability and tissue distribution compared to natural IGF-1. The "Receptor Grade" designation refers to its higher purity level compared to Media Grade variants, making it the preferred form for cell growth and receptor binding studies. Research suggests it may exhibit approximately 2.5-fold greater anabolic potency than standard IGF-1 under specific experimental conditions.

Chemical Makeup Molecular Formula: C400H625N111O115S9 | Molecular Weight: 9117.5 g/mol | Also known as: Long-(Arg3) Insulin-like Growth Factor-I, LR3-IGF-1

Research Highlights

• Tissue Anabolism — Studies in normal and catabolic murine models suggest IGF-1 LR3 may be approximately 2.5-fold more potent than standard IGF-1 in promoting anabolic outcomes including weight gain, visceral organ weight, and feed efficiency. Reduction in muscle protein degradation markers was reportedly three times greater with IGF-1 LR3 vs. IGF-1.
• Growth Hormone Deficiency — A 2005 clinical study using rhIGF-1 in growth hormone-deficient models reported an average height increase of 7cm per year, supporting the broader research potential of IGF-1 analogs in growth disorder studies.
• Metabolic Activity — Research suggests IGF-1 LR3 may stimulate glucose uptake via PI3K and AMPK signaling pathways, potentially promoting GLUT4 transporter translocation to the cell surface and enhancing cellular glucose metabolism under energy stress conditions.
• Muscle Preservation — Studies in female murine models suggest IGF-1 LR3 may counteract myostatin — a protein that inhibits muscle cell growth and differentiation — potentially reducing apoptosis and supporting lean muscle mass preservation, with its longer half-life compared to standard IGF-1 considered a key advantage.
• Tissue Distribution — Murine biodistribution studies found elevated IGF-1 LR3 concentrations in metabolically active organs including the kidneys, ovaries, and adrenal glands, suggesting tissue-specific uptake patterns distinct from natural IGF-1 — likely due to reduced IGFBP binding.

Available for research and laboratory purposes only.